Rafferty Asset Management Portfolio holdings
AUM
$30.3B
1-Year Return
18.89%
This Quarter Return
+7.65%
1 Year Return
+18.89%
3 Year Return
+101.02%
5 Year Return
+164.75%
10 Year Return
+314.44%
AUM
$8.27B
AUM Growth
+$1.17B
(+17%)
Cap. Flow
+$750M
Cap. Flow
% of AUM
9.07%
Top 10 Holdings %
Top 10 Hldgs %
43.67%
Holding
1,071
New
101
Increased
574
Reduced
272
Closed
122
Top Buys
| 1 |
VanEck Gold Miners ETF
GDX
|
$287M |
| 2 |
VanEck Junior Gold Miners ETF
GDXJ
|
$258M |
| 3 |
Apple
AAPL
|
$67.9M |
| 4 |
Microsoft
MSFT
|
$62.7M |
| 5 |
iShares China Large-Cap ETF
FXI
|
$59.7M |
Top Sells
| 1 |
iShares Russell 2000 ETF
IWM
|
$189M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
$112M |
| 3 |
Visa
V
|
$56.8M |
| 4 |
Mastercard
MA
|
$50M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
$42.1M |
Sector Composition
| 1 | Technology | 27.51% |
| 2 | Financials | 14.83% |
| 3 | Healthcare | 4.08% |
| 4 | Consumer Discretionary | 3.56% |
| 5 | Industrials | 3.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Apellis Pharmaceuticals
APLS
$3.55B
| $2.09M | 0.03% |
69,229
+38,410
| +125% | +$1.16M |
|
|
TCF
402
DELISTED
TCF Financial Corporation Common Stock
TCF
| $2.09M | 0.03% |
89,443
+23,113
| +35% | +$540K |
|
403
Voya Financial
VOYA
$7.38B
| $2.08M | 0.03% |
43,395
+17,445
| +67% | +$836K |
|
|
TBIO
404
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $2.08M | 0.03% |
152,743
+136,710
| +853% | +$1.86M |
|
405
LPL Financial
LPLA
$26.6B
| $2.08M | 0.03% |
27,108
+10,947
| +68% | +$839K |
|
406
Equity Residential
EQR
$25.5B
| $2.08M | 0.03% |
40,423
-64,002
| -61% | -$3.29M |
|
|
GBT
407
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $2.07M | 0.03% |
37,607
+22,359
| +147% | +$1.23M |
|
408
Iovance Biotherapeutics
IOVA
$901M
| $2.06M | 0.02% |
62,592
+30,227
| +93% | +$995K |
|
409
Century Communities
CCS
$2.07B
| $2.05M | 0.02% |
48,509
+7,852
| +19% | +$332K |
|
410
Karyopharm Therapeutics
KPTI
$57.2M
| $2.04M | 0.02% |
9,315
+5,503
| +144% | +$1.21M |
|
|
STL
411
DELISTED
Sterling Bancorp
STL
| $2.04M | 0.02% |
193,881
+59,932
| +45% | +$631K |
|
412
PTC Therapeutics
PTCT
$4.55B
| $2.03M | 0.02% |
43,513
+24,122
| +124% | +$1.13M |
|
413
Brookfield Infrastructure Partners
BIP
$14.1B
| $2.02M | 0.02% |
+63,659
| New | +$2.02M |
|
414
SEI Investments
SEIC
$10.8B
| $2.02M | 0.02% |
39,827
+16,004
| +67% | +$812K |
|
415
RBC Bearings
RBC
$12.2B
| $2.02M | 0.02% |
16,659
+2,777
| +20% | +$337K |
|
|
CIT
416
DELISTED
CIT Group Inc.
CIT
| $2M | 0.02% |
112,968
+48,726
| +76% | +$863K |
|
|
MNTA
417
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $2M | 0.02% |
38,099
+7,333
| +24% | +$385K |
|
418
Eagle Materials
EXP
$7.86B
| $1.98M | 0.02% |
22,951
+3,396
| +17% | +$293K |
|
419
Jack Henry & Associates
JKHY
$11.8B
| $1.98M | 0.02% |
12,184
-12,776
| -51% | -$2.08M |
|
|
KSU
420
DELISTED
Kansas City Southern
KSU
| $1.97M | 0.02% |
10,917
-924
| -8% | -$167K |
|
|
ICPT
421
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.97M | 0.02% |
47,581
+34,877
| +275% | +$1.45M |
|
422
Gen Digital
GEN
$18.2B
| $1.96M | 0.02% |
93,925
+28,317
| +43% | +$590K |
|
423
United Therapeutics
UTHR
$18.1B
| $1.96M | 0.02% |
19,355
+11,084
| +134% | +$1.12M |
|
424
Esperion Therapeutics
ESPR
$540M
| $1.95M | 0.02% |
52,436
+30,476
| +139% | +$1.13M |
|
425
FibroGen
FGEN
$48.9M
| $1.94M | 0.02% |
1,882
+881
| +88% | +$906K |
|